HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nadia Harbeck Selected Research

Doxorubicin (Adriamycin)

10/2022Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
1/2020Pembrolizumab for Early Triple-Negative Breast Cancer.
3/2010First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
1/2010Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.
5/2005Antibody therapy for breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nadia Harbeck Research Topics

Disease

343Breast Neoplasms (Breast Cancer)
05/2024 - 01/2002
179Neoplasms (Cancer)
03/2024 - 01/2002
29Neoplasm Metastasis (Metastasis)
01/2022 - 01/2002
19Triple Negative Breast Neoplasms
01/2024 - 11/2015
17Neutropenia
02/2024 - 06/2009
16Ovarian Neoplasms (Ovarian Cancer)
01/2023 - 06/2003
15Pathologic Complete Response
01/2023 - 06/2009
14Disease Progression
01/2022 - 06/2004
11Fatigue
01/2024 - 05/2014
10COVID-19
01/2023 - 01/2020
9Carcinoma (Carcinomatosis)
04/2021 - 02/2002
9Febrile Neutropenia
02/2021 - 04/2006
7Leukopenia
01/2023 - 01/2010
6Nausea
12/2023 - 07/2009
6Anemia
12/2020 - 03/2009
5Brain Neoplasms (Brain Tumor)
06/2022 - 01/2007
5Pain (Aches)
01/2020 - 01/2018
4Diarrhea
02/2024 - 04/2019
4Vomiting
12/2023 - 06/2016
4Alopecia (Baldness)
12/2023 - 07/2009
4Residual Neoplasm
09/2022 - 03/2007
4Cardiotoxicity
09/2021 - 05/2005
4Infections
02/2021 - 06/2009
4Circulating Neoplastic Cells
01/2019 - 12/2015

Drug/Important Bio-Agent (IBA)

96Hormones (Hormone)IBA
04/2024 - 01/2002
48Biomarkers (Surrogate Marker)IBA
01/2023 - 01/2002
37Trastuzumab (Herceptin)FDA Link
01/2023 - 01/2003
32ErbB Receptors (EGF Receptor)IBA
02/2024 - 03/2010
30human ERBB2 proteinIBA
01/2023 - 12/2009
24AnthracyclinesIBA
10/2022 - 04/2006
22Proteins (Proteins, Gene)FDA Link
04/2024 - 01/2002
20palbociclibIBA
01/2024 - 07/2015
20Plasminogen Activator Inhibitor 1IBA
07/2019 - 01/2002
20Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2016 - 01/2002
18Estrogen ReceptorsIBA
01/2024 - 07/2004
18Docetaxel (Taxotere)FDA Link
03/2023 - 01/2006
17Epirubicin (Ellence)FDA LinkGeneric
10/2022 - 03/2007
15Fulvestrant (Faslodex)FDA Link
10/2023 - 01/2011
15Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2022 - 11/2009
13TamoxifenFDA LinkGeneric
01/2023 - 07/2004
13Paclitaxel (Taxol)FDA LinkGeneric
01/2023 - 03/2007
12Letrozole (Femara)FDA LinkGeneric
01/2024 - 01/2007
12Ado-Trastuzumab EmtansineIBA
01/2023 - 01/2014
11abemaciclibIBA
04/2024 - 04/2019
11Aromatase InhibitorsIBA
05/2023 - 12/2007
11SteroidsIBA
01/2020 - 01/2002
11Tissue ExtractsIBA
11/2010 - 01/2002
10taxaneIBA
10/2022 - 01/2008
10Messenger RNA (mRNA)IBA
01/2022 - 07/2003
10Progesterone Receptors (Progesterone Receptor)IBA
01/2022 - 02/2005
9Cyclin-Dependent Kinase 4IBA
09/2023 - 01/2017
9Carboplatin (JM8)FDA LinkGeneric
10/2022 - 12/2011
8ParaffinIBA
02/2024 - 11/2008
8Phenobarbital (Luminal)FDA Link
01/2023 - 12/2013
8pertuzumabIBA
01/2023 - 03/2013
8Lapatinib (GW572016)FDA Link
10/2021 - 01/2008
8Plasminogen InactivatorsIBA
07/2011 - 01/2002
7Formaldehyde (Formol)FDA Link
02/2024 - 11/2008
7ribociclibIBA
09/2023 - 01/2018
7130-nm albumin-bound paclitaxelIBA
09/2022 - 12/2015
7AntigensIBA
01/2022 - 08/2002
7Capecitabine (Xeloda)FDA Link
10/2021 - 08/2005
7GemcitabineFDA Link
04/2021 - 11/2015
7Fluorouracil (Carac)FDA LinkGeneric
12/2020 - 08/2005
7EnzymesIBA
09/2017 - 02/2002
7Indicators and Reagents (Reagents)IBA
11/2009 - 06/2003
6pembrolizumabIBA
12/2023 - 01/2020
6Immunoconjugates (Immunoconjugate)IBA
10/2023 - 10/2013
6Taxoids (Taxanes)IBA
10/2022 - 04/2006
6RNA (Ribonucleic Acid)IBA
11/2021 - 04/2006
6Biological FactorsIBA
10/2021 - 01/2002
6Biosimilar PharmaceuticalsIBA
09/2020 - 01/2016
6Tumor Biomarkers (Tumor Markers)IBA
07/2011 - 11/2004
6Kallikreins (Kallikrein)IBA
03/2006 - 06/2003
5atezolizumabIBA
03/2023 - 01/2020
5Doxorubicin (Adriamycin)FDA LinkGeneric
10/2022 - 05/2005
5pegfilgrastim (Neulasta)FDA Link
02/2021 - 01/2016
5DNA (Deoxyribonucleic Acid)IBA
12/2017 - 04/2006
5Serine Proteases (Serine Protease)IBA
10/2010 - 01/2006
5ImmunosorbentsIBA
01/2006 - 02/2002
4Epidermal Growth Factor (EGF)IBA
04/2024 - 12/2008
4Cadherins (E-Cadherin)IBA
04/2024 - 10/2018
4trastuzumab deruxtecanIBA
10/2023 - 01/2022
4sacituzumab govitecanIBA
03/2023 - 04/2021
4Poly(ADP-ribose) Polymerase InhibitorsIBA
12/2022 - 01/2019
4Granulocyte Colony-Stimulating Factor (G-CSF)IBA
12/2020 - 04/2006
4LigandsIBA
10/2020 - 02/2005
4Anastrozole (Arimidex)FDA LinkGeneric
06/2020 - 12/2007
4Transcription Factors (Transcription Factor)IBA
01/2018 - 07/2007

Therapy/Procedure

205Therapeutics
05/2024 - 02/2002
102Drug Therapy (Chemotherapy)
05/2024 - 01/2002
40Neoadjuvant Therapy
01/2024 - 01/2009
32Adjuvant Chemotherapy
02/2024 - 08/2002
18Radiotherapy
02/2024 - 01/2007
10Segmental Mastectomy (Lumpectomy)
04/2023 - 05/2006
7Aftercare (After-Treatment)
05/2024 - 03/2008
6Mastectomy (Mammectomy)
12/2021 - 03/2008
5Drug Tapering
04/2024 - 01/2006
5Precision Medicine
06/2020 - 09/2008
4Immunotherapy
10/2022 - 01/2010